From "Blind Treatment" to "Precision Targeting": How Medicine Is Evolving Toward Precision Therapy

Over the past few decades, drug research and development has undergone a profound transformation from traditional chemical medicines to the era of precision medicine. Driven by rapid advances in molecular biology, genetic technology and immunology, a growing number of innovative drugs are now designed to target the key mechanisms underlying diseases.

As a company committed to tracking global pharmaceutical innovation, Dengyue Med has long monitored cutting-edge trends in innovative drug technologies and collaborated with industry partners to advance next-generation treatment modalities.

Today, modern innovative drugs can be broadly categorized by four core mechanisms of action: targeted therapy, immunotherapy, antibody-drug conjugates (ADCs), and gene/RNA therapies. These technologies are revolutionizing the treatment of numerous diseases, particularly cancer, rare disorders and genetic conditions.

1. Targeted Therapy: Precision Blockade of Disease Signaling

Targeted drugs act by identifying specific molecular targets associated with disease and blocking abnormal cellular signaling pathways, thereby halting disease progression. Compared with conventional chemotherapy, these agents offer greater precision and typically exert minimal impact on healthy cells.

For instance, targeted therapies can inhibit abnormal kinase or receptor signaling in tumor cells, suppressing cancer growth and metastasis. Representative drugs include Imatinib and Osimertinib, which have achieved groundbreaking outcomes in cancer treatment through their precise targeting of specific molecular sites.

The emergence of targeted therapy marks a pivotal shift in medicine from "broad-spectrum treatment" to "precision care".

2. Immunotherapy: Activating the Body’s Own Defense System

The core principle of immunotherapy is to harness the body’s native immune system to fight disease.

Tumor cells often employ mechanisms to "hide" from immune detection and evade attack. Immune checkpoint inhibitors lift this immunosuppression, enabling immune cells to recognize and target cancer cells once again.

Representative immune checkpoint inhibitors, such as Pembrolizumab and Nivolumab, have demonstrated remarkable efficacy across multiple cancer types.

The advancement of immunotherapy has also spurred the development of novel fields, including cell therapy, cancer vaccines and personalized immunotherapy.

3. ADC Drugs: Precision Delivery of Chemotherapeutic Payloads

Antibody–Drug Conjugates (ADCs) are widely regarded as "biological missiles" for their targeted therapeutic action.

Each ADC consists of three key components:

● Monoclonal antibody: Recognizes and binds to tumor cells

● Linker: Connects the antibody and cytotoxic payload

● Cytotoxic payload: Delivers potent anti-tumor activity

The antibody specifically identifies antigens on the surface of tumor cells, delivering the toxic payload directly into cancer cells to achieve precise elimination. Representative ADCs include Trastuzumab emtansine and Trastuzumab deruxtecan.

In recent years, ADCs have emerged as one of the fastest-growing segments in global oncology drug development.

4. Gene and RNA Therapies: Modifying Diseases at the Source

While targeted drugs act at the protein level, gene and RNA therapies operate directly on gene expression to address disease at its root cause.

This class of therapies includes:

● Gene therapy: Replaces or repairs defective genes

● siRNA therapy: Silences abnormal gene expression

● mRNA technology: Instructs cells to produce specific therapeutic proteins

● Antisense oligonucleotides (ASOs): Regulates RNA function

For example,Onasemnogene abeparvovec is used to treat spinal muscular atrophy, and Patisiran represents a breakthrough RNA interference therapy.

These technologies are unlocking new treatment possibilities for countless genetic and rare diseases that were once considered untreatable.

Future Trends: Precision Medicine and Multi-Technology Convergence

As life sciences continue to advance, drug development is poised to embrace several transformative trends:

1.  More precise target discovery: Genomics and artificial intelligence are accelerating the identification of critical disease targets.

2.  Multi-technology combination therapies: Synergistic regimens such as targeted therapy + immunotherapy, or ADC + immunotherapy, are becoming standard approaches.

3.  Personalized medicine: Tailored treatment strategies based on individual patient genetic profiles.

4.  Rapid expansion of RNA and cell therapies: RNA technology, gene editing and cell-based therapies are set to become cornerstones of next-generation medicine.

Amid this rapidly evolving innovation ecosystem, Dengyue Med remains dedicated to monitoring global advances in innovative drug technologies and partnering with industry stakeholders to explore more effective and accessible pharmaceutical solutions.